A.R.T. Advisors’s Denali Therapeutics DNLI Stock Holding History

A.R.T. Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,173	Closed	-$517K	–	65
2020 Q4	$517K	Buy	+6,173	New	+$373K	2.39%	10

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's DNLI Position: Q1 2021 in Review

A.R.T. Advisors sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 6,173 shares — an estimated $517K sold.

A.R.T. Advisors first reported a position in DNLI in Q4 2020 and held it in 1 quarter. The position peaked at $517K in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

A.R.T. Advisors reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
A.R.T. Advisors sold 6,173 Denali Therapeutics shares in Q1 2021, an estimated $517K.
A.R.T. Advisors first reported a position in Denali Therapeutics in Q4 2020 and held it in 1 quarter.
A.R.T. Advisors's Denali Therapeutics position peaked at $517K in Q4 2020.
216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on A.R.T. Advisors's 13F filing for Q1 2021, filed 17 May 2021.